Evolution of Cardiac Damage in MitraClip

Degenerative mitral valve regurgitation affects the mitral apparatus and is related to severe insufficiency. At present, surgery is the treatment of choice for patients at low risk. 

La reparación de la válvula mitral con Mitraclip es segura en pacientes de alto riesgo

Oftentimes, this disease affects the elderly and/or those at high surgical risk, edge-to-edge repair being an excellent treatment alternative. 

We all know that the different stages of ventricular function deterioration have a negative impact on disease evolution, but there is little information on the impact of edge-to-edge evolution on each of these stages.

This analysis looked at 579 patients undergoing edge-to-edge repair with MitraClip to treat degenerative mitral valve regurgitation, classified according to cardiac damage. 

Stage 0 (S0) patients showed no cardiac damage. Stage 1 (S1) showed damage to the medial portion of the left ventricle or the left atrial (defined by ejection fraction ≤60%, end diastolic diameter >55 mm, end systolic diameter >35 mm, left atrial indexed volume ≥40 ml/m2 or atrial fibrillation). Stage 2 (S2) patients showed moderate damage to the left ventricle or the left atrial (defined by left ventricular ejection fraction ≤50%, end diastolic diameter >60 mm, end systolic diameter >40 mm, left atrial indexed volume ≥60 ml/m2). And stage 3 (S3), showed right heart damage (defined as right tricuspid regurgitation or severe right ventricular function deterioration).

Read also: Prehospital Crushed vs. Integral Prasugrel in STEMI Patients with Large Myocardial Area at Risk

Patients in S0 or S1 were 84, S2 319 patients and S3 176 patients.

Mean age was 82 and 52% were women. Compared against patients in S0 or S1, patients in the more advanced stages presented more comorbidities, more hospitalization for cardiac failure and higher BNP levels.

By the end of procedure, S0 and S1 patients had residual mitral valve regurgitation ≤1+.

At 2 years, survival resulted higher in S0 and S1 patients vs. the other two stages (100% vs. 89.5% vs. 78.9% vs. 75.3%, respectively, p=0.013). All stages showed a reduction in hospitalization for cardiac failure vs. the prior year, but this reduction was higher for S= and S1 patients. 

Read also: Predictors of DCB Failure in De Novo Lesions.

There was an improvement in functional class in all groups, but the presence of functional class III-IV was more frequent in the more advanced stages. 

There was a reduction in mitral regurgitation maintained over time in all patients. 

After multivariable analysis, mortality predictors at 2 years were S2 and S3, female sex, functional class III-IV and residual mitral valve regurgitation >2+.

Conclusion

Advanced damage was associated with increased mortality risk in patients undergoing edge-to-edge repair for degenerative mitral valve regurgitation. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Cardiac Damage in Degenerative Mitral Regurgitation Treated With Transcatheter Mitral Edge-to-Edge Repair.

Reference: Atsushi Sugiura, et al. Circ Cardiovasc Interv. 2024;17:e013794. DOI: 10.1161/CIRCINTERVENTIONS.123.013794.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...